{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ADMET", "DFT", "MD simulations", "MM-GBSA", "PLIP", "VEGFR-2 inhibitors", "in vitro antiproliferative", "molecular docking", "nicotinamide"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35889478", "DateCompleted": {"Year": "2022", "Month": "07", "Day": "28"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "07", "Day": "19"}], "Language": ["eng"], "ELocationID": ["4606", "10.3390/molecules27144606"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "14", "PubDate": {"Year": "2022", "Month": "Jul", "Day": "19"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects.", "Abstract": {"AbstractText": ["A nicotinamide-based derivative was designed as an antiproliferative VEGFR-2 inhibitor with the key pharmacophoric features needed to interact with the VEGFR-2 catalytic pocket. The ability of the designed congener ((<i>E</i>)-N-(4-(1-(2-(4-benzamidobenzoyl)hydrazono)ethyl)phenyl)nicotinamide), compound <b>10</b>, to bind with the VEGFR-2 enzyme was demonstrated by molecular docking studies. Furthermore, six various MD simulations studies established the excellent binding of compound <b>10</b> with VEGFR-2 over 100 ns, exhibiting optimum dynamics. MM-GBSA confirmed the proper binding with a total exact binding energy of -38.36 Kcal/Mol. MM-GBSA studies also revealed the crucial amino acids in the binding through the free binding energy decomposition and declared the interactions variation of compound <b>10</b> inside VEGFR-2 via the Protein-Ligand Interaction Profiler (PLIP). Being new, its molecular structure was optimized by DFT. The DFT studies also confirmed the binding mode of compound <b>10</b> with the VEGFR-2. ADMET (in silico) profiling indicated the examined compound's acceptable range of drug-likeness. The designed compound was synthesized through the condensation of <i>N</i>-(4-(hydrazinecarbonyl)phenyl)benzamide with <i>N</i>-(4-acetylphenyl)nicotinamide, where the carbonyl group has been replaced by an imine group. The in-vitro studies were consonant with the obtained in silico results as compound <b>10</b> prohibited VEGFR-2 with an IC<sub>50</sub> value of 51 nM. Compound <b>10</b> also showed antiproliferative effects against MCF-7 and HCT 116 cancer cell lines with IC<sub>50</sub> values of 8.25 and 6.48 \u03bcM, revealing magnificent selectivity indexes of 12.89 and 16.41, respectively."]}, "AuthorList": [{"Identifier": ["0000-0002-2546-8035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": ["0000-0003-3709-1930"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": ["0000-0003-0893-6703"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Elkady", "ForeName": "Hazem", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Gobaara", "ForeName": "Ibraheem M M", "Initials": "IMM"}, {"Identifier": ["0000-0001-6489-6035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Bshra A", "Initials": "BA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry Department, Faculty of Science, New Valley University, El-Kharja 72511, Egypt."}], "LastName": "Husein", "ForeName": "Dalal Z", "Initials": "DZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Cairo 12613, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}], "GrantList": [{"GrantID": "PNURSP2022R142", "Agency": "Princess Nourah bint Abdulrahman University", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "25X51I8RD4", "NameOfSubstance": "Niacinamide"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-2"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Niacinamide"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-2"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "WHO  Cancer, Fact Sheet.  [(accessed on 13 November 2021)].  Available online:  https://www.who.int/news-room/fact-sheets/detail/cancer."}, {"Citation": "El-Dash Y., Elzayat E., Abdou A.M., Hassan R.A. Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition. Bioorg. Chem. 2021;114:105137. doi: 10.1016/j.bioorg.2021.105137.", "ArticleIdList": ["10.1016/j.bioorg.2021.105137", "34237644"]}, {"Citation": "Nishida N., Yano H., Nishida T., Kamura T., Kojiro M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2006;2:213. doi: 10.2147/vhrm.2006.2.3.213.", "ArticleIdList": ["10.2147/vhrm.2006.2.3.213", "PMC1993983", "17326328"]}, {"Citation": "Quesada A.R., Mu\u00f1oz-Ch\u00e1puli R., Medina M.A. Anti-angiogenic drugs: From bench to clinical trials. Med. Res. Rev. 2006;26:483\u2013530. doi: 10.1002/med.20059.", "ArticleIdList": ["10.1002/med.20059", "16652370"]}, {"Citation": "Olsson A.-K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling? In control of vascular function. Nat. Rev. Mol. Cell Biol. 2006;7:359\u2013371. doi: 10.1038/nrm1911.", "ArticleIdList": ["10.1038/nrm1911", "16633338"]}, {"Citation": "Carmeliet P.J.O. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69:4\u201310. doi: 10.1159/000088478.", "ArticleIdList": ["10.1159/000088478", "16301830"]}, {"Citation": "Alsaif N.A., Taghour M.S., Alanazi M.M., Obaidullah A.J., Alanazi W.A., Alasmari A., Albassam H., Dahab M.A., Mahdy H.A. Identification of new [1, 2, 4] triazolo [4,3-a] quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorg. Med. Chem. 2021;46:116384. doi: 10.1016/j.bmc.2021.116384.", "ArticleIdList": ["10.1016/j.bmc.2021.116384", "34479065"]}, {"Citation": "Shah A.A., Kamal M.A., Akhtar S.J.C.D.M. Tumor angiogenesis and VEGFR-2: Mechanism, pathways and current biological therapeutic interventions. Curr. Drug Metab. 2021;22:50\u201359. doi: 10.2174/1389200221666201019143252.", "ArticleIdList": ["10.2174/1389200221666201019143252", "33076807"]}, {"Citation": "Elrazaz E.Z., Serya R.A., Ismail N.S., Albohy A., Abou El Ella D.A., Abouzid K.A. Discovery of Potent Thieno [2, 3-d] pyrimidine VEGFR-2 Inhibitors: Design, Synthesis and Enzyme Inhibitory Evaluation Supported by Molecular Dynamics Simulations. Bioorg. Chem. 2021;113:105019. doi: 10.1016/j.bioorg.2021.105019.", "ArticleIdList": ["10.1016/j.bioorg.2021.105019", "34091286"]}, {"Citation": "Sana S., Reddy V.G., Bhandari S., Reddy T.S., Tokala R., Sakla A.P., Bhargava S.K., Shankaraiah N. Exploration of carbamide derived pyrimidine\u2014Thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. Eur. J. Med. Chem. 2020;200:112457. doi: 10.1016/j.ejmech.2020.112457.", "ArticleIdList": ["10.1016/j.ejmech.2020.112457", "32422489"]}, {"Citation": "Peng F.-W., Liu D.-K., Zhang Q.-W., Xu Y.-G., Shi L. VEGFR-2 inhibitors and the therapeutic applications thereof: A patent review (2012\u20132016) Expert Opin. Ther. Patents. 2017;27:987\u20131004. doi: 10.1080/13543776.2017.1344215.", "ArticleIdList": ["10.1080/13543776.2017.1344215", "28621580"]}, {"Citation": "Sun S., Zhang J., Wang N., Kong X., Fu F., Wang H., Yao J. Design and discovery of quinazoline-and thiourea-containing sorafenib analogs as EGFR and VEGFR-2 dual TK inhibitors. Molecules. 2017;23:24. doi: 10.3390/molecules23010024.", "ArticleIdList": ["10.3390/molecules23010024", "PMC5943947", "29295519"]}, {"Citation": "Abdel-Mohsen H.T., Abdullaziz M.A., El Kerdawy A.M., Ragab F.A., Flanagan K.J., Mahmoud A.E., Ali M.M., El Diwani H.I., Senge M.O. Targeting receptor tyrosine kinase VEGFR-2 in hepatocellular cancer: Rational design, synthesis and biological evaluation of 1, 2-disubstituted benzimidazoles. Molecules. 2020;25:770. doi: 10.3390/molecules25040770.", "ArticleIdList": ["10.3390/molecules25040770", "PMC7071059", "32053964"]}, {"Citation": "Cavasotto C.N., Aucar M.G., Adler N.S. Computational chemistry in drug lead discovery and design. Int. J. Quantum Chem. 2019;119:e25678. doi: 10.1002/qua.25678.", "ArticleIdList": ["10.1002/qua.25678"]}, {"Citation": "Filipe H.A., Loura L.M. Molecular Dynamics Simulations: Advances and Applications. Molecules. 2022;27:2105. doi: 10.3390/molecules27072105.", "ArticleIdList": ["10.3390/molecules27072105", "PMC9000824", "35408504"]}, {"Citation": "Ojo O.A., Ojo A.B., Okolie C., Nwakama M.-A.C., Iyobhebhe M., Evbuomwan I.O., Nwonuma C.O., Maimako R.F., Adegboyega A.E., Taiwo O.A. Deciphering the interactions of bioactive compounds in selected traditional medicinal plants against Alzheimer\u2019s diseases via pharmacophore modeling, auto-QSAR, and molecular docking approaches. Molecules. 2021;26:1996. doi: 10.3390/molecules26071996.", "ArticleIdList": ["10.3390/molecules26071996", "PMC8037217", "33915968"]}, {"Citation": "Elton D.C., Boukouvalas Z., Fuge M.D., Chung P.W. Deep learning for molecular design\u2014A review of the state of the art. Mol. Syst. Des. Eng. 2019;4:828\u2013849. doi: 10.1039/C9ME00039A.", "ArticleIdList": ["10.1039/C9ME00039A"]}, {"Citation": "Keith J.A., Vassilev-Galindo V., Cheng B., Chmiela S., Gastegger M., Mu\u00fcller K.-R., Tkatchenko A. Combining machine learning and computational chemistry for predictive insights into chemical systems. Chem. Rev. 2021;121:9816\u20139872. doi: 10.1021/acs.chemrev.1c00107.", "ArticleIdList": ["10.1021/acs.chemrev.1c00107", "PMC8391798", "34232033"]}, {"Citation": "C\u00e1ceres E.L., Tudor M., Cheng A.C. Deep learning approaches in predicting ADMET properties. Futur. Med. Chem. 2020;12:1995\u20131999. doi: 10.4155/fmc-2020-0259.", "ArticleIdList": ["10.4155/fmc-2020-0259", "33124448"]}, {"Citation": "Ciallella H.L., Zhu H. Advancing computational toxicology in the big data era by artificial intelligence: Data-Driven and mechanism-driven modeling for chemical toxicity. Chem. Res. Toxicol. 2019;32:536\u2013547. doi: 10.1021/acs.chemrestox.8b00393.", "ArticleIdList": ["10.1021/acs.chemrestox.8b00393", "PMC6688471", "30907586"]}, {"Citation": "Tielens F., Gierada M., Handzlik J., Calatayud M. Characterization of amorphous silica based catalysts using DFT computational methods. Catal. Today. 2020;354:3\u201318. doi: 10.1016/j.cattod.2019.03.062.", "ArticleIdList": ["10.1016/j.cattod.2019.03.062"]}, {"Citation": "Pracht P., Bohle F., Grimme S. Automated exploration of the low-energy chemical space with fast quantum chemical methods. Phys. Chem. Chem. Phys. 2020;22:7169\u20137192. doi: 10.1039/C9CP06869D.", "ArticleIdList": ["10.1039/C9CP06869D", "32073075"]}, {"Citation": "Seidel T., Schuetz D.A., Garon A., Langer T. The pharmacophore concept and its applications in computer-aided drug design. Prog. Chem. Org. Nat. Prod. 2019;110:99\u2013141.", "ArticleIdList": ["31621012"]}, {"Citation": "Adnane L., Trail P.A., Taylor I., Wilhelm S.M. Sorafenib (BAY 43-9006, Nexavar\u00ae), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597\u2013612.", "ArticleIdList": ["16757355"]}, {"Citation": "Yousef R.G., Sakr H.M., Eissa I.H., Mehany A.B., Metwaly A.M., Elhendawy M.A., Radwan M.M., ElSohly M.A., Abulkhair H.S., El-Adl K. New quinoxaline-2 (1 H)-ones as potential VEGFR-2 inhibitors: Design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations. New J. Chem. 2021;45:16949\u201316964. doi: 10.1039/D1NJ02509K.", "ArticleIdList": ["10.1039/D1NJ02509K", "34175720"]}, {"Citation": "Ran F., Li W., Qin Y., Yu T., Liu Z., Zhou M., Liu C., Qiao T., Li X., Yousef R.G. Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: Design, synthesis, and biological evaluation. Oxidative Med. Cell. Longev. 2021;2021:1\u201321. doi: 10.1155/2021/8321400.", "ArticleIdList": ["10.1155/2021/8321400", "PMC8568530", "34745424"]}, {"Citation": "Legler C., Brown N., Dunbar R., Harness M., Nguyen K., Oyewole O., Collier W., Spectroscopy B. Scaled quantum mechanical scale factors for vibrational calculations using alternate polarized and augmented basis sets with the B3LYP density functional calculation model. Acta Part A Mol. Biomol. Spectrosc. 2015;145:15\u201324. doi: 10.1016/j.saa.2015.02.103.", "ArticleIdList": ["10.1016/j.saa.2015.02.103", "25766474"]}, {"Citation": "Husein D.Z., Hassanien R., Khamis M. Cadmium oxide nanoparticles/graphene composite: Synthesis, theoretical insights into reactivity and adsorption study. RSC Adv. 2021;11:27027\u201327041. doi: 10.1039/D1RA04754J.", "ArticleIdList": ["10.1039/D1RA04754J", "PMC9037664", "35480026"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Gobaara I.M.M., Alsfouk A.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches. Processes. 2022;10:1391. doi: 10.3390/pr10071391.", "ArticleIdList": ["10.3390/pr10071391"]}, {"Citation": "Wang T., Husein D.Z. Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: Disposing of waste with waste. Environ. Sci. Pollut. Res. 2022;23:1\u201328. doi: 10.1007/s11356-022-20050-2.", "ArticleIdList": ["10.1007/s11356-022-20050-2", "35460480"]}, {"Citation": "El-Zahabi M.A., Sakr H., El-Adl K., Zayed M., Abdelraheem A.S., Eissa S.I., Elkady H., Eissa I.H. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorg. Chem. 2020;104:104218. doi: 10.1016/j.bioorg.2020.104218.", "ArticleIdList": ["10.1016/j.bioorg.2020.104218", "32932121"]}, {"Citation": "Li X., Jiang Y., Peterson Y.K., Xu T., Himes R.A., Luo X., Yin G., Inks E.S., Dolloff N., Halene S. Design of hydrazide-bearing HDACIs based on panobinostat and their p53 and FLT3-ITD dependency in antileukemia activity. J. Med. Chem. 2020;63:5501\u20135525. doi: 10.1021/acs.jmedchem.0c00442.", "ArticleIdList": ["10.1021/acs.jmedchem.0c00442", "PMC7684764", "32321249"]}, {"Citation": "El-Adl K., El-Helby A.-G.A., Sakr H., Elwan A. [1, 2, 4] Triazolo [4, 3-a] quinoxaline and [1, 2, 4] triazolo [4, 3-a] quinoxaline-1-thiol-derived DNA intercalators: Design, synthesis, molecular docking, in silico ADMET profiles and anti-proliferative evaluations. New J. Chem. 2021;45:881\u2013897. doi: 10.1039/D0NJ02990D.", "ArticleIdList": ["10.1039/D0NJ02990D"]}, {"Citation": "Parmar D.R., Soni J.Y., Guduru R., Rayani R.H., Kusurkar R.V., Vala A.G., Talukdar S.N., Eissa I.H., Metwaly A.M., Khalil A., et al. Discovery of new anticancer thiourea-azetidine hybrids: Design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Bioorg. Chem. 2021;115:105206. doi: 10.1016/j.bioorg.2021.105206.", "ArticleIdList": ["10.1016/j.bioorg.2021.105206", "34339975"]}, {"Citation": "Elkady H., Elwan A., El-Mahdy H.A., Doghish A.S., Ismail A., Taghour M.S., Elkaeed E.B., Eissa I.H., Dahab M.A., Mahdy H.A. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J. Enzym. Inhib. Med. Chem. 2022;37:397\u2013410. doi: 10.1080/14756366.2021.2015343.", "ArticleIdList": ["10.1080/14756366.2021.2015343", "PMC8725875", "34961427"]}, {"Citation": "Elkaeed E.B., Youssef F.S., Eissa I.H., Elkady H., Alsfouk A.A., Ashour M.L., El Hassab M.A., Abou-Seri S.M., Metwaly A.M. Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease. Int. J. Mol. Sci. 2022;23:6912. doi: 10.3390/ijms23136912.", "ArticleIdList": ["10.3390/ijms23136912", "PMC9266348", "35805916"]}, {"Citation": "El-Adl K., Sakr H.M., Yousef R.G., Mehany A.B., Metwaly A.M., Elhendawy M.A., Radwan M.M., ElSohly M.A., Abulkhair H.S., Eissa I.H. Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. Bioorg. Chem. 2021;114:105105. doi: 10.1016/j.bioorg.2021.105105.", "ArticleIdList": ["10.1016/j.bioorg.2021.105105", "34175720"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "7", "Day": "1"}, {"Year": "2022", "Month": "7", "Day": "16"}, {"Year": "2022", "Month": "7", "Day": "18"}, {"Year": "2022", "Month": "7", "Day": "27", "Hour": "1", "Minute": "35"}, {"Year": "2022", "Month": "7", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "19"}], "PublicationStatus": "epublish", "ArticleIdList": ["35889478", "PMC9317904", "10.3390/molecules27144606", "molecules27144606"]}}], "PubmedBookArticle": []}